Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer

Table 1 Baseline characteristics of the study patients n (%)

Demographics	Total (n = 38)	Adjuvant group (Group 1, n = 25)	Neoadjuvant group (Group 2, n = 13)
Median age (yr)	55.5	54.3	50.1
Range	38.6-73.8	42.1-68.8	38.6-73.8
Age groups
30-50	16	10	6
51-60	10	8	2
61-75	12	7	5
Primary site
Ovarian	37 (97)	24 (96)	13 (100)
Fallopian tube	1 (3)	1 (4)	0 (0)
Tumor stage
IIB	1 (2.6)	0 (0)	1 (7.7)
IIC	2 (5.3)	2 (8)	0 (0)
IIIA	3 (7.9)	2 (8)	1 (7.7)
IIIB	5 (13.2)	4 (16)	1 (7.7)
IIIC	22 (57.9)	14 (56)	8 (61.5)
IV	2 (5.3)	0 (0)	2 (15.4)
Recurrent (n = 3)	3 (7.9)
IIB/C	2 (8)	2 (8)	0 (0)
IIIB	1 (2.6)	1 (2.6)	0 (0)
Histology
High grade serous	37 (97.3)	25 (100)	12 (93.3)
Poorly differentiated	1 (2.7)	0 (0)	1 (6.7)
Surgery optimal debulking (< 1 cm)	23 (60.5)	17 (68)	6 (46.1)
No optimal debulking	3 (7.9)	1 (4)	2 (15.4)
Data unavailable	12 (31.6)	7 (28)	5 (38.5)
Baseline CA 125 value after surgery1
Normal	9 (23.7)	2 (8)	7 (53.8)
Abnormal	15 (39.5)	12 (48)	3 (23)
Not available	14 (36.8)	11 (44)	3 (23)
BRCA 1/2 mutations (all germline)
Positive	7 (18.5)	4 (16)	3 (23.1)
Negative	16 (42.1)	12 (48)	4 (30.8)
Unknown	15 (39.4)	8 (32)	7 (53.8)

¹Baseline CA 125 value: defined as CA 125 value taken on the day of starting adjuvant treatment, intravenous or intraperitoneal, or in the 2 wk period before chemotherapy.